A part of MilliporeSigma

News Articles and Interviews

 
 
Billerica, Massachusetts: 10 January 2017
Sustainable Downstream Processing of Vaccines: The DiViNe Consortium (article published in EPM Magazine)
Priyabrata Pattnaik, director, Worldwide Vaccine Initiative, MilliporeSigma talks about the need for downstream processing within vaccine production.
Read article 

Billerica, Massachusetts: 27 September 2016
MilliporeSigma's AFS Water Systems Reduce Water Consumption (article published in R&D Magazine)
R&D Magazine features an R&D 100 Flashback, chosen from our R&D 100 archive of winners. This flashback is MilliporeSigma's AFS Water Systems, which won in 2015.
Read article 

Billerica, Massachusetts: 18 November 2015
The Making Of MilliporeSigma (article published in Chemical and Engineering News)
On Nov. 18, Merck KGaA, Darmstadt, Germany, closed on the biggest acquisition in its 347-year history: The $17.0 billion purchase of the research-chemical supply house Sigma-Aldrich.
Read article 

Billerica, Massachusetts: 29 September 2015
EMD Millipore Accepts Silver Stevie® Award for AFS® E Water Purification Systems at the 2015 American Business Awards℠
EMD Millipore, the Life Science division of Merck KGaA, Darmstadt, Germany, accepted a Silver Stevie® Award for its AFS® E Water Purification Systems at a banquet held on Friday, September 11 in San Francisco. The award was conferred by The American Business Awards℠, the premier business awards program in the United States.
Read article

China: 15 April 2015
Both pharmaceutical companies and their suppliers share an optimistic view on the Chinese biopharmaceutical market
As China strengthens its legal system and pharmaceutical companies demand increasingly advanced technologies, EMD Millipore, a technology-based company that provides products and services for biopharmaceutical companies, sees big opportunities for expansion in the Chinese market.
Read article

China: 13 April 2015
How do new biotechnologies promote the development of the pharmaceutical industry?
Interview with Dr. Udit Batra, CEO and President of EMD Millipore

In recent years, emerging biotechnologies covering areas as diverse as gene editing, next-generation genetic sequencing, and disposable biological products, have not only driven the rapid development of preclinical medicine, they have also created huge business opportunities for pharmaceutical companies, transforming the entire industry landscape.
Read article

China: 08 April 2015
EMD Millipore tells media in Shanghai it seeks to improve its position in the Chinese market
Recently, Dr. Udit Batra, CEO and President of EMD Millipore, and other executives from the company, attended EMD Millipore's media briefing in Shanghai. Dr. Udit Batra shared his views on the company's Chinese market development strategy, the recent acquisition of Sigma-Aldrich, and other issues with reporters.
Read article

China: 08 April 2015
Further Expansion in the Chinese Market
Interview with Dr. Udit Batra, CEO and President of EMD Millipore
On March 31, 2015, Dr. Udit Batra, CEO and President, EMD Millipore was interviewed by three reporters including Process Industry, in Shanghai. Dr. Udit Batra introduced EMD Millipore's business profile and future plans, emphasizing that EMD Millipore will focus on growth in emerging markets, particularly China. In the interview, Dr. Udit Batra also shared details of EMD Millipore's philosophy and recent trends.
Read article

China: 08 April 2015
GSK takes over Novartis' vaccines business amid large-scale integration of multinational pharmaceutical companies in China
As China's macroeconomic slow-down is gradually accepted as the "new normal" trend, foreign pharmaceutical companies are suffering ever more problems arising from rapid expansion and excessive infrastructure investment in recent years. These companies are trying to adapt to the new normal by taking necessary measures in terms of compliance, mergers and acquisitions, personnel restructuring, and so on.
Read article

China: 07 April 2015
Biotechnology Research & Development and the Chinese Market
Oriental Morning Post: How did you benefit from the pharmaceutical industry acquisitions in China last year?
Udit Batra: This has two benefits. One is to bring global products into China, and the second is to take Chinese products globally. EMD Millipore supports the processes both ways.
Read article